Hematopoietic stem cell mobilization: A clinical protocol

Methods in Molecular Biology

Volumn 904, Issue , 2012, Pages 69-77

  Pesek, Gina ^a   Cottler Fox, Michele ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Apheresis; Clinical practice; Growth factors; HPC; Mobilization

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLERIXAFOR;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; HUMAN; LEUKAPHERESIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

EID: 84934438778     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-943-3_5     Document Type: Article

References (15)

1. Tricot G, Jagannath S, Vesole D et al (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596
2. Morris CL, Siegel E, Barlogie B et al (2003) Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120:413-423
3. Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that Influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555
4. Rosenbaum ER, O'Connell B, Cottler-Fox M (2012) Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis. Cytotherapy 14(4):461-466
5. Rivadeneyra-Espinoza L, Perez-Romano B, Gonzalez-Flores A et al (2006) Instrument-and protocol-dependent variation in the enumeration of CD34+ cells by flow cytometry. Transfusion 46:530-536
6. Bender JG, To LB, Williams S et al (1992) defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329-341
7. Weaver CH, Hazelton B, Birch R et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969
8. Suh C, Kim S, Kim SH et al (2004) Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 44:1762-1768
9. Park KU, Kim SH, Suh C et al (2001) Correlation of hematopoietic progenitor cell count determined by the SE-automated hema-tology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 67:42-47
10. Dao MA, Arevelo J, Nolta JA (2003) Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood 101:112-118
11. Hess DA, Wirthlin L, Craft TP et al (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 107:2162-2169
12. Rosenbaum ER, Nakagawa M, Pesek G et al (2009) A 15 hour extended dosing-collection interval for Plerixafor is at least as effective as the standard 10 hour interval. Blood 114:2152
13. Product information. Leukine (sargramostim). Seattle, WA: Bayer Healthcare Pharmaceuticals, April, 2008
14. Product information. Neupogen (filgrastim). Thousand Oaks, CA: Amgen Inc., 1991-1996.
15. Product information. Mozobil (plerixafor). Cambridge, MA: Genzyme Corporation, December, 2008